H.C. Wainwright raised the firm’s price target on Xoma (XOMA) to $123 from $117 and keeps a Buy rating on the shares after the company acquired Pulmokine and its interest in seralutinib, in development for pulmonary arterial hypertension. The addition of seralutinib to Xoma’s “broad” royalty base represents the second whole company acquisition in 2024, the analyst tells investors in a research note. The firm says the size of Xoma royalty pipeline “explodes with another boost to” its confidence to the company’s “deal making creativity.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XOMA:
- Xoma Royalty acquires Pulmokine for $20M
- XOMA Royalty’s Third Quarter 2024 Financial Insights
- Xoma reports Q3 EPS ($1.59), consensus (44c)
- Xoma Corp. (XOMA) Q3 Earnings Cheat Sheet
- Xoma enters $15M royalty monetization arrangement with Twist Bioscience
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
